Key findings reported in the year include: Cardiovalve TARGET CE Pivotal Study (Europe) Immediate outcomes in the first 105 patients demonstrated 93.7% achieved ≤mild tricuspid regurgitation.

Favorable mortality and heart failure hospitalization rates, along with improved functional status, observed among recipients of LuX-Valve device for severe symptomatic tricuspid regurgitation.